• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Atara Biotherapeutics Inc.

    6/11/24 5:03:11 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATRA alert in real time by email
    S-8 1 d767564ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 11, 2024.

    Registration No. 333-    

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ATARA BIOTHERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-0920988
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

    2380 Conejo Spectrum Street, Suite 200

    Thousand Oaks, California 91320

    (805) 623-4211

    (Address, including zip code and telephone number, of Registrant’s principal executive offices)

    Atara Biotherapeutics, Inc. 2024 Equity Incentive Plan

    Pascal Touchon

    Chief Executive Officer

    2380 Conejo Spectrum Street, Suite 200

    Thousand Oaks, California 91320

    (805) 623-4211

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Eric Hyllengren

    Chief Financial Officer

    2380 Conejo Spectrum Street, Suite 200

    Thousand Oaks, California 91320

    (805) 623-4211

     

    Carlton Fleming

    Sidley Austin LLP

    555 California Street, Suite 2000

    San Francisco, California 94104

    (415) 772-1200

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Atara Biotherapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 6,900,000 shares of Common Stock, $0.0001 par value per share, of the Registrant (the “Common Stock”), issuable to eligible persons under the Atara Biotherapeutics, Inc. 2024 Equity Incentive Plan.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). Documents containing the information required by Part I of the Registration Statement will be sent or given to plan participants as specified by Rule 428(b)(1) of the Securities Act.

    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, which includes audited financial statements for the Registrant’s latest fiscal year, filed with the SEC on March 28, 2024 (the “2023 Form 10-K”).

     

      (b)

    The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 9, 2024.

     

      (c)

    The Registrant’s Current Reports on Form 8-K, filed with the SEC on January  8, 2024, January  9, 2024, February  23, 2024, March  29, 2024, and June 11, 2024.

     

      (d)

    The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the SEC on July 16, 2014, including any amendments or reports filed for the purposes of updating this description, including Exhibit 4.5 to the 2023 Form 10-K.

     

      (e)

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.


    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act.

    As permitted by the Delaware General Corporation Law, the Registrant’s Certificate of Incorporation provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Registrant shall be eliminated to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Under the Delaware General Corporation Law, no director will be personally liable to the Registrant or the Registrant’s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

     

      •  

    for any breach of the duty of loyalty to the Registrant or the Registrant’s stockholders;

     

      •  

    for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

      •  

    for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; or

     

      •  

    for any transaction from which the director derived an improper personal benefit.

    As permitted by the Delaware General Corporation Law, the Registrant’s Bylaws provide that:

     

      •  

    the Registrant is required to indemnify the Registrant’s directors and executive officers to the fullest extent not prohibited by Delaware law, subject to limited exceptions;

     

      •  

    the Registrant may indemnify the Registrant’s other officers, employees and agents as set forth in the Delaware General Corporation Law;

     

      •  

    the Registrant is required to advance expenses to the Registrant’s directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and

     

      •  

    the rights conferred in the Bylaws are not exclusive.

    The Registrant has entered into indemnification agreements with each of the Registrant’s directors and executive officers that require the Registrant to indemnify these persons all direct and indirect costs of any type or nature whatsoever, including attorneys’ fees, witness fees, and other out of pocket costs of whatever nature, incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Registrant or is or was serving or at any time serves at the request of the Registrant as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

    The Registrant has purchased insurance on behalf of any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    ITEM 8. EXHIBITS

     

    Exhibit
    Number

     

    Description

      4.1 (1)   Amended and Restated Certificate of Incorporation of Atara Biotherapeutics, Inc.
      4.2 (2)   Second Amended and Restated Bylaws of Atara Biotherapeutics, Inc.
      4.3 (3)   Form of common stock certificate.
      4.4*   Atara Biotherapeutics, Inc. 2024 Equity Incentive Plan.
      5.1*   Opinion of Sidley Austin LLP.
     23.1*   Consent of Sidley Austin LLP (included in Exhibit 5.1).
     23.2*   Consent of Deloitte & Touche LLP, independent registered public accounting firm.
     24.1*   Power of Attorney (included on the signature page of this Form S-8).
      107*   Calculation of Filing Fee Table.

     

    (1)

    Filed as Exhibit 3.2 to Registrant’s Registration Statement on Form S-1 (File No. 333-196936), filed with the SEC on June 20, 2014, and incorporated herein by reference.

    (2)

    Filed as Exhibit 3.1 to Registrant’s Registration Statement on Form 8-K (File No. 001-36548), filed with the SEC on September 27, 2022, and incorporated herein by reference.

    (3)

    Filed as Exhibit 4.1 to Registrant’s Registration Statement on Form S-1 (File No. 333-196936), filed with the SEC on July 10, 2014, and incorporated herein by reference.

    *

    Filed herewith.

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.


    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than for the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on this 11th day of June, 2024.

     

    ATARA BIOTHERAPEUTICS, INC.
    By:   /s/ Pascal Touchon
     

    Pascal Touchon

    President and Chief Executive Officer

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pascal Touchon and Eric Hyllengren, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Pascal Touchon

    Pascal Touchon, D.V.M.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      June 10, 2024

    /s/ Eric Hyllengren

    Eric Hyllengren

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 10, 2024

    /s/ Carol G. Gallagher

    Carol G. Gallagher, Pharm.D.

       Chairman of the Board   June 10, 2024

    /s/ Matthew K. Fust

    Matthew K. Fust

       Director   June 10, 2024

    /s/ William K. Heiden

    William K. Heiden

       Director   June 10, 2024

    /s/ Ameet Mallik

    Ameet Mallik

       Director   June 10, 2024

    /s/ Maria Grazia Roncarolo

    Maria Grazia Roncarolo, M.D.

       Director   June 10, 2024
    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA

    DatePrice TargetRatingAnalyst
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    11/9/2023Outperform → In-line
    Evercore ISI
    11/9/2023Buy → Neutral
    H.C. Wainwright
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    7/20/2022$8.00 → $3.00Neutral → Sell
    Citigroup
    7/13/2022$10.00Overweight → Neutral
    JP Morgan
    7/13/2022$16.00 → $5.00Buy → Hold
    Stifel
    5/10/2022$15.00 → $8.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd bought $186,372 worth of shares (19,335 units at $9.64) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    7/21/25 9:00:05 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/15/23 5:07:08 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd sold $489,019 worth of shares (80,554 units at $6.07) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    1/14/26 9:16:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd exercised 48,737 shares at a strike of $0.00 and covered exercise/tax liability with 1 shares (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    12/1/25 5:00:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Nguyen Anhco sold $38,437 worth of shares (2,915 units at $13.19), decreasing direct ownership by 4% to 64,974 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/19/25 4:55:17 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by Evercore ISI

    Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

    11/9/23 9:00:28 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral

    11/9/23 7:32:43 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

    SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the Agency is unable to approve the tabelecleucel Biologics License Application (BLA) in its present form. We are surprised and deeply disappointed by the FDA's decision, particularly given the urgent and life-threatening unmet medical need faced by patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of standard-of-c

    1/12/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

    Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million milestone payment from Pierre Fabre Laboratories Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Pos

    11/12/25 9:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    SEC Filings

    View All

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    1/12/26 4:00:16 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    1/2/26 4:01:26 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

    SCHEDULE 13D/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/25 4:19:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Leadership Updates

    Live Leadership Updates

    View All

    CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform

    Experienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. "We are delighted to welcome Pascal to our Board of Directors," said Dominik Escher, Ph.D., Chairman of CDR-Life's Board of Directors. "Pascal's remarkable track record in developing and commercializing transformative thera

    5/28/25 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

    5/16/25 8:50:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

    3/23/22 7:30:00 AM ET
    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    $ATRA
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

    11/5/24 4:01:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

    Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

    11/1/23 8:30:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 4:17:31 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/12/24 1:29:52 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care